# Verra Therapeutics, Inc. — Form D

Verra Therapeutics, Inc. of LANSING, NY, a company, filed a Form D exempt-offering notice with the SEC on 2026-02-18. The offering totals $450K, of which $205K was reported sold. Industry: Biotechnology.

## Offering

- Filed: 2026-02-18
- Form: D
- Accession: 0002111997-26-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $450K
- Amount sold: $205K
- Remaining: $245K
- Minimum investment: $10K
- Investors: 6
- Date of first sale: 2024-12-16
- Security types: equity
- Revenue range: $1 - $1,000,000
- SEC file number: 021-573922

## Issuer

- Name: Verra Therapeutics, Inc.
- CIK: 0002111997
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2024
- Address: 1939 EAST SHORE DR. SUITE 5, LANSING, NY, 14882
- Phone: 607 227 6828

## Officers, directors & promoters (3)

| Name | Role | Location |
| --- | --- | --- |
| Jeffrey Lucas Calkins | Director | Lansing, NY |
| Christopher Lucas Prince | Director | Lansing, NY |
| Christopher Lucas Prince | Executive Officer | Lansing, NY |

## More

- [CIK 2111997 on SEC EDGAR (source of record)](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=2111997&type=&dateb=&owner=include&count=40)
- [This page as markdown (for LLM agents)](https://search.stillhousedata.com/formd/0002111997-26-000001.md)
- [Search all SEC filings, advisers and people on Adviser Search](https://search.stillhousedata.com/)

---

Source: public SEC filing data via Adviser Search (https://search.stillhousedata.com).
Agents: this data is also queryable via MCP tools and read-only SQL — see https://search.stillhousedata.com/llms.txt.